“Researchers have made significant strides in the field of inflammatory disease treatment. By exploring the therapeutic potential of an epitope from an anti-tetranectin antibody, they developed P2-1, a water-soluble derivative. This targeted therapy significantly improved survival rates and reduced inflammation in sepsis models, and lessened arthritis severity and pain in RA models. The study introduces a novel drug discovery strategy, transforming harmful antibody insights into targeted therapeutics for the HMGB1-pCTS-L axis.”